Milestone Pharmaceuticals Q3 2025 Earnings Report

Milestone Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.17
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Milestone Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Milestone Pharmaceuticals Announcement Details

• Quarter: Q3 2025
• Date: 11/11/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, November 11, 2025
• Conference Call Time: 8:00AM ET

Milestone Pharmaceuticals (NASDAQ:MIST), Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs. Preclinical and early clinical studies are aimed at demonstrating safety, tolerability and proof of concept in patient populations with high unmet medical need. The company leverages strategic collaborations and research partnerships to accelerate development and expand its scientific expertise.

Founded in the United States and headquartered in San Diego, California, Milestone Pharmaceuticals operates with a management team experienced in respiratory drug development. The company continues to pursue regulatory pathways for its lead programs and is preparing for later-stage clinical trials. Through a combination of internal innovation and external partnerships, Milestone seeks to bring new treatment options to patients suffering from debilitating respiratory disorders.